ArticleFrontiers in surgery2025
Analysis of factors influencing health-related quality of life in patients with femoropopliteal atherosclerotic occlusive disease treated with drug-coated balloons 12 months after surgery.
Article in Frontiers in surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Patients with femoropopliteal (FP) occlusive disease encounter considerable obstacles concerning health-related quality of life (HRQoL), which serve as the primary objectives of their interventions. While Drug-Coated Balloons (DCBs) present potential advantages, they are not constitute definitive cures. There is a paucity of research concerning postoperative HRQoL in these patients. This study evaluates HRQoL 12 months post-DCB treatment and examines influencing risk factors through a multicenter cross-sectional study. Methods: This retrospective, multicenter study involved 1012 patients with FP occlusive disease who underwent DCB at 8 vascular centers from August 2021 to December 2023. Data on initial hospitalizations and 12-month follow-up were gathered, and logistic regression was utilized to examine the influencing factors. Results: According to the median HRQoL at 12 months postoperatively, patients were categorized into low ( Conclusions: Overall, the Rutherford classification progression over 12 months was significantly positively linked to HRQoL 12 months postoperatively. Conversely, HRQoL was notably diminished in patients who exhibited arterial calcification, elevated postoperative Rutherford classification, and experienced TLR. Nevertheless, intervention approach, DCB length and diameter had no significant relationship to postoperative HRQoL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.